ATE538781T1 - Neue verwendung von peptidverbindungen zur behandlung von dyskinesie - Google Patents

Neue verwendung von peptidverbindungen zur behandlung von dyskinesie

Info

Publication number
ATE538781T1
ATE538781T1 AT05750546T AT05750546T ATE538781T1 AT E538781 T1 ATE538781 T1 AT E538781T1 AT 05750546 T AT05750546 T AT 05750546T AT 05750546 T AT05750546 T AT 05750546T AT E538781 T1 ATE538781 T1 AT E538781T1
Authority
AT
Austria
Prior art keywords
peptide compounds
new use
treat dyskinesia
dyskinesia
treat
Prior art date
Application number
AT05750546T
Other languages
English (en)
Inventor
Thomas Stoehr
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Application granted granted Critical
Publication of ATE538781T1 publication Critical patent/ATE538781T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05750546T 2004-05-18 2005-05-17 Neue verwendung von peptidverbindungen zur behandlung von dyskinesie ATE538781T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57193204P 2004-05-18 2004-05-18
EP04011833A EP1604654A1 (de) 2004-05-18 2004-05-18 Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
PCT/EP2005/005355 WO2005110390A1 (en) 2004-05-18 2005-05-17 Novel use of peptide compounds for treating dyskinesia

Publications (1)

Publication Number Publication Date
ATE538781T1 true ATE538781T1 (de) 2012-01-15

Family

ID=34925049

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05750546T ATE538781T1 (de) 2004-05-18 2005-05-17 Neue verwendung von peptidverbindungen zur behandlung von dyskinesie

Country Status (12)

Country Link
US (1) US7416864B2 (de)
EP (2) EP1604654A1 (de)
JP (1) JP4938656B2 (de)
AT (1) ATE538781T1 (de)
AU (1) AU2005244440A1 (de)
BR (1) BRPI0511291A (de)
CA (1) CA2565051C (de)
EA (1) EA200602129A1 (de)
ES (1) ES2380510T3 (de)
MX (1) MXPA06013300A (de)
UA (1) UA86808C2 (de)
WO (1) WO2005110390A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604656A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
JP5307550B2 (ja) * 2005-12-20 2013-10-02 エヌピーエス ファーマシューティカルズ インコーポレイテッド フッ素化化合物
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
CA2672494A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
EP2214657A1 (de) 2007-10-23 2010-08-11 UCB Pharma GmbH Verbindungen zur behandlung von demyelisationserkrankungen
CA2774569A1 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
MX2013005974A (es) 2010-12-02 2013-07-29 Ucb Pharma Gmbh Formulacion de lacosamida de administracion una vez al dia.
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU84891A1 (fr) * 1983-06-30 1985-03-29 Continental Pharma Derives de l'acide 2-aminoacetique,leur preparation et utilisation ainsi que compositions pharmaceutiques contenant ces derives
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
ATE111460T1 (de) * 1990-06-15 1994-09-15 Synthelabo 2-(aminoalkyl)-5-(arylalkyl)1,3-dioxanderivate, ihre herstellung und ihre anwendung in der therapeutik.
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
EP0900567A3 (de) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazolin-4-on AMPA Antagonisten zur Behandlung von motorischen Fehlfunktionen verbunden mit Dopaminagonist Therapie
AU8676301A (en) * 2000-08-25 2002-03-04 Res Corp Technologies Inc New uses for amino acid anticonvulsants
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.

Also Published As

Publication number Publication date
EP1753414A1 (de) 2007-02-21
JP4938656B2 (ja) 2012-05-23
CA2565051C (en) 2013-01-22
JP2007538037A (ja) 2007-12-27
US20050261204A1 (en) 2005-11-24
CA2565051A1 (en) 2005-11-24
MXPA06013300A (es) 2007-02-22
BRPI0511291A (pt) 2007-12-04
EA200602129A1 (ru) 2007-04-27
EP1753414B1 (de) 2011-12-28
WO2005110390A1 (en) 2005-11-24
UA86808C2 (ru) 2009-05-25
EP1604654A1 (de) 2005-12-14
US7416864B2 (en) 2008-08-26
AU2005244440A1 (en) 2005-11-24
ES2380510T3 (es) 2012-05-14

Similar Documents

Publication Publication Date Title
ATE538781T1 (de) Neue verwendung von peptidverbindungen zur behandlung von dyskinesie
ATE387194T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE534379T1 (de) Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
ATE544449T1 (de) Neue verwendung von peptidverbindungen zur behandlung von amyothropher lateralsklerose
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE602005026508D1 (de) Monozyklische heterozyklen als kinase-hemmer
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
DE602005006938D1 (de) Gebrauchslimitierendes elektronisches Schlüsselsystem für Plasmagerät zur Behandlung von Gewebeoberflächen
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA200700702A1 (ru) Аналоги локсапина и способы их применения
CL2007002389A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de obesidad, hirsutismo, hipertricosis y verrugas viricas.
ATE445402T1 (de) Neue verwendung von pde5-hemmern
ATE553090T1 (de) Cathepsincysteinproteasehemmer
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE410235T1 (de) Behandlung von ballastwasser
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
ATE358495T1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
DE502004011486D1 (de) Antioxidationsmittel für organisches material und verfahren zur behandlung desselben